KR20130026315A - Kimchi composition having prevention and improvement function of allergic diseases - Google Patents

Abstract

PURPOSE: A kimchi composition containing Acanthopanax senticosus, Mori folium, and Glycyrrhizae radix is provided to suppress histamine secretion and inflammatory cytokine generation. CONSTITUTION: A kimchi composition which prevents and treats allergic diseases contains Acanthopanax senticosus, Mori folium, Polygonatum odoratum cv., and Glycyrrhizae radix. The composition contains 30-80 parts by weight of Mori folium. The composition contains 15-50 parts by weight of Polygonatum odoratum cv. The composition contains 10-40 parts by weight of Glycyrrhizae radix. [Reference numerals] (AA,DD,GG,JJ) Control Kimchi; (BB,EE,HH,KK) Embodiment 1; (CC,FF,II,LL) Embodiment 3

Description

Kimchi composition having the ability to prevent and improve allergic diseases {KIMCHI COMPOSITION HAVING PREVENTION AND IMPROVEMENT FUNCTION OF ALLERGIC DISEASES}

The present invention relates to a composition for preventing and improving allergic diseases.

With the recent increase in allergic diseases such as allergic rhinitis and atopic dermatitis, the demand for safe and effective anti-allergic products is increasing. Such anti-allergic products are widely applied not only to medicines such as antihistamines, but also to functional foods and articles, because there is an increasing tendency to recognize allergic diseases as diseases to be improved and managed throughout life.

For this reason, recently, a pharmaceutical composition comprising an anthraquinone derivative (Korean Patent Publication No. 10-2011-0085517), a pharmaceutical composition for preventing or improving allergy containing an extract of Lagerstroemia as an active ingredient (Korean Patent Publication No. 10- In addition to pharmaceuticals and foods such as 2011-0050938), anti-allergic properties in various fields, such as cosmetic compositions for preventing or improving allergic diseases (Korean Patent Publication No. 10-2011-0041705) containing lion cucurbita extract as active ingredients Product development is taking place.

However, even if the food and pharmaceutical composition having an anti-allergic activity, most of them are administered as a separate medicinal or health food, and the technology to prepare general foods commonly consumed by Koreans such as kimchi and pickles as anti-allergic foods It was difficult. This is because it is difficult to maintain the antiallergic activity during fermentation and ripening even if the antiallergic composition is added due to the characteristics of fermented food such as kimchi.

Accordingly, the present inventors, while continuing to study the anti-allergic fermented food, when the kimchi is prepared by the addition of prickly gallium, upper leaf, roundle and licorice, the kimchi confirmed that it has anti-allergic activity and completed the present invention.

It is an object of the present invention to provide a composition for the prevention and improvement of allergic diseases.

Another object of the present invention is to provide an antiallergic food.

In order to achieve the above object, the present invention provides a composition for the prevention and improvement of allergic diseases, including thorny galpi, upper lobe, roundle and licorice.

In another aspect, the present invention provides anti-allergic foods, including psoriasis, upper leaf, roundle and licorice.

The anti-allergic composition and food of the present invention inhibit the production of allergen-type hypersensitivity, i.e., allergen-producing IgE. That is, the present invention not only inhibits the secretion of histamine that is directly involved in causing allergy by having a function of regulating (suppressing) a superior Th2 type immune response by an allergen causing allergy, but also inhibits the release of NO and inflammatory cytokines. It has the function of suppressing production.

Figure 1 shows the effect on IgE production by allergen sensitization in mice after oral administration of Example 3 to the mice.
Figure 2 shows the effect on IgG production upon oral administration of Examples 1 and 3 in mice.
Figure 3 shows the effect of the subisotype of the IgG antibody when orally administered to Examples 1 and 3 in the mouse.
4 shows the effect of Examples 1 and 3 on IgA production upon oral administration to mice.
Figure 5 shows the production pattern of cytokines produced upon oral administration of the sample to mice.

The present invention relates to a composition for the prevention and improvement of allergic diseases, including thorns and leaves, upper lobes, roundles and licorice.

The present invention also relates to anti-allergic foods, including thorns, leaves, roundes and licorice.

Hereinafter, the present invention will be described in detail.

The composition of the present invention may include 30 to 80 parts by weight of the upper lobe, based on 100 parts by weight of prickly pear. In addition, the composition of the present invention may include 15 to 50 parts by weight of rounds, based on 100 parts by weight. In addition, the composition of the present invention may include 10 to 40 parts by weight of licorice with respect to 100 parts by weight of the visible. If the upper leaf, round and licorice are included in less than 30 parts by weight, 15 parts by weight and 10 parts by weight, respectively, or more than 80 parts by weight, 50 parts by weight, 40 parts by weight, respectively, the allergic inhibitory effect may be less. However, even if the drug is somewhat lowered, by having a certain allergic inhibitory effect by the mixture of thorny galpigo, upper leaf, roundle, licorice, it does not belong to the scope of the present invention to fall outside the above range.

The composition of the present invention has the ability to inhibit the production of IgE. Therefore, the composition of the present invention generally suppresses IgE-mediated type I immune hypersensitivity reactions, namely allergic reactions generally referred to. For example, the composition of the present invention can alleviate, ameliorate and prevent IgE-mediated bronchial asthma, urticaria, allergic rhinitis, atopic dermatitis, anaphylaxis and the like. The composition of the present invention also has antihistamine activity.

The allergic disease of the present invention refers to a disease in which hypersensitivity reactions are induced to cause allergens to cause allergens, and abnormalities occur in the body due to a rapid mechanism during hypersensitivity reactions. For example, the allergic disease of the present invention may be one or more selected from the group consisting of atopic dermatitis, allergic rhinitis, asthma, allergic conjunctivitis, allergic enteritis, anaphylaxis and urticaria (including atopic urticaria), but are not limited thereto. It is not.

The composition for the prevention and improvement of allergic diseases, including thorny golpi, upper leaf, roundle and licorice of the present invention may be a composition comprising a kimchi culture of thorny golpi, upper leaf, roundle and licorice as an active ingredient.

The kimchi culture is obtained from kimchi prepared by the addition of thorny galpipi, upper leaf, roundle and licorice. For example, the kimchi culture can be obtained from kimchi prepared by adding pruning gall, upper leaf, round and licorice to kimchi seasoning, and the kimchi solution (ie, kimchi broth) of the kimchi, or extract of kimchi crushed, etc. Can be.

In addition, the present invention relates to an anti-allergic food to which a composition for preventing and improving allergic diseases including thorns, gallium, round leaves, licorice and licorice is added.

The present invention also relates to anti-allergic foods to which kimchi cultures of saplings, upper leaves, rounds and licorice are added.

The anti-allergic food of the present invention may be a general food material, and is not particularly limited. For example, the food of the present invention may be a fermented food, the fermented food may be kimchi, pickles, miso, gochujang, soy sauce and the like.

The composition for preventing and improving allergic diseases of the present invention may be a pharmaceutical composition or a food composition.

The pharmaceutical composition for the prevention and treatment of allergic diseases of the present invention may include 0.01 to 99 parts by weight of the thorny red pepper, upper leaf, roundle and licorice, preferably 0.02 to 80 parts by weight, based on 100 parts by weight of the composition. can do. However, this may be increased or decreased depending on the needs of the doser, and may be appropriately increased or decreased depending on the diet, nutritional status, severity of allergic reactions, and exposure to allergens.

The pharmaceutical compositions of the present invention can be administered orally or parenterally, can be applied and used, and can be used in the form of general pharmaceutical preparations. Preferred pharmaceutical preparations include oral preparations such as tablets, hard or soft capsules, solutions, suspensions and the like, which can be used in the form of excipients in conventional pharmaceutically acceptable carriers such as oral preparations, Binders, disintegrants, lubricants, solubilizers, suspending agents, preservatives or extenders can be used.

The dosage of the pharmaceutical composition of the present invention may be determined by a specialist depending on various factors such as the patient's condition, age, weight, severity of allergic reactions, the degree of exposure of allergens, and generally 0.1 mg to 10 g per kg of adult. , Preferably from 1 mg to 5 g. In addition, it is intended to contain a daily dose of the pharmaceutical composition or a dose of 1/2, 1/3 or 1/4 thereof per unit dosage form, and may be administered 1 to 6 times a day. However, in the case of long-term intake, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.

In addition, the composition for preventing and improving allergic diseases of the present invention may be a food composition. The food is not limited to, but not limited to, health supplements, health functional foods, functional foods, and the like, and natural foods, processed foods, and general food materials, including the addition of the prickly pear, lettuce, round and licorice of the present invention.

Food composition comprising the thorns of the present invention, upper leaf, round and licorice, can be added as it is or used in combination with other food or food composition, can be suitably used in accordance with conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, improvement, or therapeutic treatment). In general, the thorny red pepper, upper leaf, roundle and licorice of the present invention may be added in an amount of 0.1 to 90 parts by weight, preferably 1 to 60 parts by weight, based on 100 parts by weight of the raw material of the food or beverage in the manufacture of the food or beverage. have. The effective dose of the yeast hydrolyzate may be used in accordance with the effective dose of the pharmaceutical composition, but may be less than the above range in the case of long-term intake, such as for the purpose of improving the overall constitution, since the active ingredient has no problem in terms of safety. It may also be used in an amount above the above range.

 There is no particular limitation on the kind of the food. The food composition comprising the prickly pear, upper leaf, round and licorice may be used in the form of oral preparations, such as tablets, hard or soft capsules, solutions, suspensions, etc., these preparations are acceptable conventional carriers, such as For example, in the case of oral preparations, excipients, binders, disintegrants, glidants, solubilizers, suspending agents, preservatives or extenders may be used.

Examples of the food that can be added to the thorny red pepper, upper leaf, round and licorice, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups , Beverages, teas, drinks, alcoholic beverages and vitamin complexes, and other nutritional supplements, but are not limited to these types of food.

Hereinafter, the present invention will be described in more detail by the following examples and experimental examples. However, the following examples and experimental examples are intended to illustrate the contents of the present invention, but the scope of the invention is not limited by the examples and the experimental examples.

<Example 1-2 and Comparative Example 1-5>

After mixing the ingredients in the composition shown in Table 1, water was added 10 times the weight of the total weight was extracted by hot water at 100 ℃ for 4 hours. The residue was removed from the extract and lyophilized using a lyophilizer to prepare a sample (Example 1-2, Comparative Example 1-5).

<Example 3>

The plant extract lyophilisate of Example 1 was mixed at a rate of 5 g per 100 g of kimchi seasoning to prepare a plant extract lyophilized mixed kimchi seasoning. Kimchi was prepared using the mixed kimchi seasoning and Chinese cabbage and aged for 1 week at 4 ℃. Kimchi liquid was collected by centrifugation of aged kimchi (Example 3). The concentration of kimchi collected was about 20 mg / ml.

<Example 4>

The plant extract lyophilisate of Example 2 was mixed at a rate of 5 g per 100 g of kimchi seasoning to prepare a plant extract lyophilized mixed kimchi seasoning. Kimchi was prepared using the mixed kimchi seasoning and Chinese cabbage and aged for 1 week at 4 ℃. Kimchi liquid was collected by centrifugation of aged kimchi (Example 4). The concentration of the plant extract lyophilisate contained in the collected kimchi solution was about 20 mg / ml.

<Experimental Example 1>

Example 1-2 and Comparative Example 1-5 were administered to ICR mouse intraperitoneally, respectively. After 30 minutes, compound 48/80 was treated with SD mice at a dose of 5 mg / kg to prepare anaphylactic shock model mice, and the survival rate of the mice was examined over time. As a control group, a compound group treated with compound 48/80 after 1 mg saline was used. Each experimental and control group was used 20 animals.

As a result, it was confirmed that the acute shock inhibitory activity of Examples 1 and 2 including prickly pear, upper lobe, roundle, and licorice is high (Table 2). In particular, it was recognized that Example 1 had the most significant effect of suppressing the death of mice caused by the release of histamine causing allergy, and Example 1 was used in subsequent experiments.

Experimental Example 2 Effect of Oral Administration of Samples on the Production of Antibodies

As an allergen, 5 ug of OVA was mixed with alum hydroxide (alum; 1 mg / mouse), a commercial adjuvant, to sensitize mice. Each immunogen was subcutaneously immunized three times at two week intervals, and antiserum collection was prepared from each mouse after 5 days of boosting immunity (final immunity). Examples 1 and 3 were administered at 100 mg / kg body weight every day until 10 days before the allergen immunity, 2-3 days interval after allergen immunity until the final tertiary immunization. As a control, kimchi solution obtained by centrifugation of general kimchi was used, and was administered in the same manner as in Example 3.

Total antibody titer and IgE, IgG production for each antigen present in the serum were measured, and Examples 1 and 3 were also analyzed for subisotypes of antibodies produced after simultaneous immunization with allergens. Total antibody titer and IgE, IgG production amount for each antigen present in serum were measured by ELISA method, and Examples 1 and 3 were also analyzed for subisotype of antibody produced after simultaneous immunization with allergen. The total IgE content of serum was performed according to the manufacturer's instructions using an ELISA kit (BD Biosciences, Franklin Lakes, NJ, USA) for measuring mouse IgE, and analysis of immunoglobulin subisotypes was specific for each subisotype of mouse immunoglobulin. ELISA kit (Pierce. Rockford, USA) using the secondary antibody was performed. Antiserum was used 500 times diluted to determine the subisotype of the antibody produced.

<2-1> IgE Antibody Production

Oral administration of the general kimchi solution showed slightly lower IgE production activity than the allergen alone control group, and the oral administration group of Example 3 showed significantly lower IgE production activity than the control kimchi. At the same time, the oral administration group of Example 1 also showed a significantly low IgE production activity. Therefore, oral administration of Examples 1 and 3 was confirmed to have the activity of inhibiting IgE-mediated immune hypersensitivity (Fig. 1).

<2-2> Effect on the Production of IgG and its Subisotypes

Administration of Examples 1 and 3 has been shown to inhibit IgG1 production (FIG. 2), It showed a similar tendency of antibody production as IgE antibody.

However, the antibody activity of IgG2a and IgG2b type, which is affected by the cytokines of the Th1 propensity, was elevated compared to the control (Fig. 3).

<2-3> Effect on the Production of IgA

Administration of Example 1 and Example 3 raised IgA antibody titers against antigen OVA. IgA antibody is an antibody mainly involved in mucosal immunity, and the antibody titer of IgA in blood is increased when oral administration of the present invention suggests that the present invention has an activity to enhance intestinal immunity (FIG. 4).

Experimental Example 3 Investigation of Cytokine Production Patterns Produced by Splenocytes of Immune Mouse

In Examples 1 and 3, it was confirmed that the IgG2-type antibody was promoted to Th1 type, and among the antibodies of the Th2 type, it was mainly active to inhibit IgE type antibody production. On the other hand, the production effect of IgA directly involved in mucosal immunity showed a significantly higher activity in the control group of the general kimchi solution and oral administration of Example 3, this result seems to be because kimchi itself enhances mucosal immunity . However, Example 3 did not increase the production of significantly higher IgA compared to general kimchi.

The function of effector B cells involved in humoral immunity is the production of cytokines such as IL-2, IFN-γ, GM-CSF, or IL-4, produced by Th2-type helper T cells. Regulated by IL-6 and IL-10. Th1-type cytokine is reported to be involved in B cell production of IgG2 type antibodies, and Th2-type cytokine has been reported to promote differentiation into B cells mainly producing IgG1 and IgE type antibodies. Therefore, the determination of the subisotype of the antibody against the antigen can be explained mainly by the cytokine production form produced by Th1 and Th2 cells. Therefore, experiments on the production mode of cytokine produced by splenocytes of each immunized mouse after antigen OVA roll stimulation are performed. Was carried out. The amount of Th1-type and Th2-type cytokine produced by re-stimulating OVA used as an antigen by separating splenocytes of immunized mice by mixing OVA alone or with the present invention was examined.

As a result, the Example 1 administration group (OVA + Alum + Example 1) to which the medicinal plant extract was administered, and the Example 3 administration group (OVA + Alum + Example 3), which was a sample Kimchi administration group containing medicinal plants, were the control group which immunized only the antigen OVA. Compared with (Alum + OVA group), the production of Th1-type propensity IFN-γ and IL-2 was significantly enhanced, and representative Th2-type IL-4 was inhibited (FIG. 5). Therefore, Examples 1 and 3 were considered to inhibit the production of IL-4, thereby inhibiting the conversion of IgG1 type antibody against OVA to IgE. Therefore, oral administration of the sample of the present invention was determined to significantly inhibit the type 1 hypersensitivity reaction caused by IgE mediated.

Experimental Example 4 Inhibitory Effect of Histamine Secretion and Inflammatory Components from Mast Cells

<4-1> Histamine Analysis

Example 4 was administered to the abdominal cavity of SD mice, and 30 minutes later, compound 48/80 (5 mg / kg body weight) was injected to induce anaphylactic shock. After 15 minutes from Compound 48/80 treatment, blood was taken from the mice, plasma was isolated, and histamine was measured using histamine EIA kit according to the principle of competition. The mortality rate of mice due to acute shock was measured, and the results of the histamine measurement were confirmed.

As a result, the experimental group administered at 100 mg / kg body weight of Example 4 showed about 32% of histamine-induced inhibitory activity compared to the control group (sample-free group), and the inhibitory effect was 10% at the 20 mg / kg body weight group ( Table 3). Therefore, Example 4 was found to inhibit histamine in a concentration dependent manner. In addition, the 100 mg / kg body weight group of Example 4, the mice survived 100%, it was confirmed again the antihistamine ability of Example 4 (Table 4).

Claims (11)

Composition for the prevention and improvement of allergic diseases, including thorns, gallium, upper leaves, roundes and licorice.
The method of claim 1,
With respect to 100 parts by weight of prickly pear, the upper leaf is a composition comprising 30 to 80 parts by weight.
The method of claim 1,
With respect to 100 parts by weight of prickly gourd, the composition comprises 15 to 50 parts by weight of roundness.
The method of claim 1,
With respect to 100 parts by weight of liquor, licorice is a composition comprising 10 to 40 parts by weight. The method of claim 1,
A composition, characterized in that it has the ability to inhibit the production of IgE or IgG.
The method of claim 1,
A composition characterized by having antihistamine activity.
The method of claim 1,
The allergic disease is at least one selected from the group consisting of atopic dermatitis, allergic rhinitis, asthma, allergic conjunctivitis, allergic enteritis, anaphylaxis and urticaria.
The method of claim 1,
A composition for the prevention and improvement of allergic diseases, including kimchi cultures of prickly pear, upper leaf, roundle and licorice as active ingredients.
The method of claim 8,
The kimchi culture is a composition, characterized in that obtained from kimchi prepared by the addition of prickly thorn, upper leaf, roundle and licorice.
The anti-allergic food which added the composition of any one of Claims 1-9.
11. The food of claim 10, wherein the food is kimchi.

Images